Patients in the intervention group presenting to the emergency department with a history of type 2 diabetes and blood glucose of ≥ 200 mg/dL received insulin aspart every 2 hours and, if admitted to the emergency department, began daily insulin detemir in the intervention group. Those given usual care were treated as per hospital physicians.

Autor: Bernard JB, Munoz C, et al.

Fecha: 27/02/2012

Temas relacionados: Basal insulin, bolus insulin, detemir, insulin aspart, rapid acting insulin, glycaemic control, type 2

A 32-week randomised crossover trial that investigated whether insulin detemir reduces the propensity for weight gain as a result of reduced energy intake and/or increased energy expenditure.

Autor: Zachariah S, Sheldon B, et al.

Fecha: 27/02/2012

Temas relacionados: Basal-bolus, body weight, detemir, insulin detemir, NPH, type 1 diabetes, weight

The impact of non-severe hypoglycaemic events (NSHEs) was assessed using a 20 minute Internet survey in the United States, United Kingdom, Germany and France. Topics included reasons for, duration of, and impact of NSHE(s) on diabetes and disease management.

Autor: Brod M; Christensen T; et al.

Fecha: 27/02/2012

Temas relacionados: Hypoglycaemia, patient perceptions, disease management

6-week pilot study investigating the long-term effects of continuous administration of glucagon-like peptide (GLP-1).

Autor: Zander et al.

Fecha: 01/09/2011

Temas relacionados: function, insulin, type 2, glycaemic target, GLP-1

En pacientes con diabetes tipo 2, liraglutida una vez al día logró un control de la glucemia similar, redujo el peso corporal y disminuyó la incidencia de hipoglucemia en comparación con glimepirida, cuando se combinaron con el tratamiento de base metformina.

Autor: Nauck et al.

Fecha: 01/09/2011

Temas relacionados: liraglutide, patient, rosiglitazone, type 2, oral antidiabetic, GLP-1

LEAD-4 Met + TZD: a 26-week, double-blind, placebo-controlled trial assessing the efficacy and safety of the GLP-1 receptor agonist, liraglutide, when added to metformin and rosiglitazone in type 2 diabetes.

Autor: Zinman B et al.

Fecha: 01/09/2011

Temas relacionados: GLP-1, liraglutide, patient, rosiglitazone, type 2, tolerability, HbA1c, oral antidiabetic

26-week, randomised trial comparing the safety and efficacy of lirgalutide, placebo and insulin glargine, all as add-on treatment to metformin and glimepiride.

Autor: Russell-Jones et al.

Fecha: 01/09/2011

Temas relacionados: insulin, liraglutide, treatment, weight, glycaemic target, GLP-1

The incretin effect is attenuated in patients with type 2 diabetes, partly as a result of impaired beta cell responsiveness to glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This study investigated whether 4 weeks of near-normalisation of blood glucose level could improve insulin responses to GIP and GLP-1 in patients with type 2 diabetes.

Autor: Højberg et al.

Fecha: 01/09/2011

Temas relacionados: blood glucose, incretin, insulin, patient, treatment, type 2, GLP-1

Trial comparing the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day or placebo with glimepiride (2–4 mg/day) on glycaemic control, body weight and safety in type 2 diabetes.

Autor: Marre et al.

Fecha: 01/09/2011

Temas relacionados: GLP-1, incretin, insulin, liraglutide, rosiglitazone, type 2, weight

Unlike most antihyperglycaemic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists have a glucose-dependent action and promote weight loss. This study compared the effi cacy and safety of liraglutide, a human GLP-1 analogue, with exenatide, an exendin-based GLP-1 receptor agonist.

Autor: Buse et al.

Fecha: 01/09/2011

Temas relacionados: GLP-1, liraglutide, type 2, weight

A 26-week, randomised, parallel-group, open-label trial comparing liraglutide versus sitagliptin for patients with type 2 diabetes with inadequate glycaemic control with metformin.

Autor: Pratley

Fecha: 01/09/2011

Temas relacionados: GLP-1, liraglutide, type 2, HbA1c, blood glucose, oral antidiabetic

Randomized, double-blind, placebo-controlled, crossover study, on the effect of NN2211, a long-acting GLP-1 derivative, on beta-cell sensitivity in 10 patients with type 2 diabetes.

Autor: Chang et al.

Fecha: 01/09/2011

Temas relacionados: function, GLP-1, liraglutide, patient, type 2

Study investigating the dose-response relationship for GLP-1 with respect to glucose-induced insulin secretion in patients with type 2 diabetes and in control subjects matched for age, sex, and weight, using a graded intravenous glucose infusion protocol.

Autor: Kjems et al.

Fecha: 01/09/2011

Temas relacionados: function, GLP-1, insulin, liraglutide, patient, type 2, weight

The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin compared with addition of placebo or glimepiride to metformin in patients with type 2 diabetes previously treated with oral antidiabetes (OAD) therapy.

Autor: Nauck et al.

Fecha: 01/09/2011

Temas relacionados: liraglutide, patient, rosiglitazone, type 2, oral antidiabetic, GLP-1

This study investigated the onset of treatment effects overtime observed for liraglutide in combination with oral antidiabetic drugs (OADs).  This analysis included those patients from the LEAD 1, 2 and 4 studies who were randomised to liraglutide 1.2 mg, liraglutide 1.8 mg, active competitor or placebo.

Autor: Gallwitz et al.

Fecha: 01/09/2011

Temas relacionados: liraglutida, HbA1c, treatment, oral antidiabetic therapy, fasting plasma glucose, body weight, systolic blood pressure

An overview of the available pharmacodynamic data of insulin detemir and insulin glargine derived using the glucose clamp technique.

Autor: Heise T; Pieber TR

Fecha: 5/16/2011

Temas relacionados: basal, detemir, insulin, blood glucose, Farmacocinética

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE™ study.

Autor: Blonde et al.

Fecha: 5/16/2011

Temas relacionados: basal, detemir, insulin, patient, titration, glycaemic target, inicio

Time-action profiles of the novel albumin-bound basal insulin analogue NN344 with those of insulin detemir and insulin glargine in individuals with type 2 diabetes.

Autor: Klein et al.

Fecha: 01/04/2010

Temas relacionados: basal, detemir, insulin, type 2, Farmacocinética

A double-blind, randomised, crossover study assessing 24-hour glycaemic control with once-daily insulin detemir or once-daily insulin glargine in patients with type 2 diabetes.

Autor: King AB

Fecha: 5/16/2011

Temas relacionados: glycaemic target, basal, detemir, insulin, type 2, treatment, HbA1c, blood glucose, Farmacocinética

Compare the effectiveness and tolerability of insulin detemir versus NPH administered QD together with at least one OAD in poorly controlled type 2 diabetes and the different administration times of insulin detemir.

Autor: Philis-Tsimikas et al.

Fecha: 5/16/2011

Temas relacionados: basal, detemir, insulin, oral antidiabetic, tolerability, type 2, inicio

Improved glycemic control with insulin detemir once-daily in combination with sitagliptin / metformin vs. sitagliptin / metformin + sulfonylurea.

Autor: Hollander P et al.

Fecha: 5/16/2011

Temas relacionados: inicio

Starting treatment with detemir + sitagliptin and discontinue sulfonylureas improves efficiency and security features similar to the addition of sitagliptin to a system of sulfonylureas.  Sub-analysis from TRANSITION™ study.

Autor: Rašlová K et al.

Fecha: 5/16/2011

Temas relacionados: inicio

STEPwise™ study randomised of 48 weeks duration: treatment of intensification with the addition of aspartic insulin in terms of intake or postprandial glucose values in subjects with DM2.

Autor: Meneghini LF et al.

Fecha: 5/16/2011

Temas relacionados: intensificación

Less weight gain and hypoglycaemia with insulin detemir once-daily than with insulin NPH in intensification of insulin therapy in patients with DM2 and overweight: PREDICTIVE^® BMI clinical trial.

Autor: Fajardo Montañana C et al,

Fecha: 5/16/2011

Temas relacionados: intensificación

A three-year open-label, multicenter trial, evaluating 708 patients who had suboptimal glycated haemoglobin levels while taking metformin and sulfonylurea therapy.

Autor: Holman RR et al.

Fecha: 5/16/2011

Temas relacionados: biphasic, insulin, oral antidiabetic, type 2, prandial, patient, intensificación

A 6-month, prospective, randomised, open-label trial assessing the effects of once-daily basal insulin replacement using insulin detemir versus NPH insulin in basal-bolus therapy combined with regular human insulin in patients with type 1 diabetes.

Autor: Russell-Jones D et al.

Fecha: 5/16/2011

Temas relacionados: basal, determir, insulin, type 1, treatment, HbA1c, bolus, dosage, intensificación

Mechanism of the differentiating effect on the weight of analogue of prolonged detemir action in patients with DM1.

Autor: Zachariah S et al.

Fecha: 5/16/2011

Temas relacionados: intensificación

Effects of insulin detemir and NPH insulin on renal sodium, fluid retention and weight in patients with DM2.

Autor: Hendriksen K et al.

Fecha: 5/16/2011

Temas relacionados: cambio

Moving from NPH twice-daily to Levemir^® once-daily in basal-bolus regimen in DM1 and DM2 enhances control and security.

Autor: Aczel et al.

Fecha: 5/16/2011

Temas relacionados: cambio

Change of NPH detemir insulin once-daily on basal-bolus regimen in patients with diabetes mellitus: data from the European cohort PREDICTIVE™ study.

Autor: Sreenan S et al.

Fecha: 5/16/2011

Temas relacionados: cambio

Switching patients from insulin glargine to insulin detemir in a basal-bolus regimen in routine clinical practice: results from the large, multinational, observational PREDICTIVE™ study.

Autor: Yenigun M et al.

Fecha: 5/16/2011

Temas relacionados: glycaemic target, basal, detemir, insulin, type 2, blood glucose, patient, treatment, bolus, cambio

Comparison of the long-term glycaemic control and safety of insulin aspart (IAsp) versus regular human insulin (HI).

Autor: Raskin P. et al.

Fecha: 01/04/2010

Temas relacionados: type 1 diabetes, insulin aspart, rapid acting insulin analogue, mealtime insulin, bolus insulin, basal-bolus

Study was to assessing the safety and efficacy of insulin aspart (IAsp) versus regular human insulin (HI) in basal-bolus therapy with NPH insulin in pregnant women with type 1 diabetes.

Autor: Mathiesen ER. et al.

Fecha: 01/04/2010

Temas relacionados: pregnancy, hypoglycaemia, pregnant, women, insulin aspart, human insulin, rapid acting insulin analogue

This study assessed maternal and cord blood insulin antibody levels in a subset of pregnant women with type 1 diabetes who were treated with a rapid acting insulin analogue.

Autor: McCance DR. et al.

Fecha: 01/04/2010

Temas relacionados: human insulin, insulin antibody, insulin aspart, pregnancy, type 1 diabetes, rapid acting insulin analogue

This article reviews published evidence of patient-reported outcomes associated with insulin therapy over the past 3 decades in patients with type 1 and type 2 diabetes who used vial and syringe for insulin delivery compared to those who used insulin pens.

Autor: Molife C. et al.

Fecha: 01/04/2010

Temas relacionados: patient-reported outcomes, type 1 diabetes, type 2 diabetes, insulin therapy, vial and syringe, insulin pens

Maintaining tight glycaemic control is an important issue for patients with type 2 diabetes. This review discusses the role of insulin in managing type 2 diabetes, patient education and counseling on insulin use and the features of newer insulin regimens and modern delivery devices.

Autor: Rakel RE

Fecha: 01/04/2010

Temas relacionados: acceptance, adherence, insulin, insulin pen, primary care physician, type 2 diabetes, insulin analogue, modern delivery devices

Compare the injection force of three insulin delivery pens during injection of 20 U insulin at three speeds, using two types of needles.

Autor: Asakura T.

Fecha: 01/04/2010

Temas relacionados: insulin delivery pens, prefilled insulin pens, injection force, thin wall needles, extra thin wall needle

Compare the dosing accuracy of two prefilled insulin pens at dosages of 10 IU and 30 IU.

Autor: Weise A.

Fecha: 01/04/2010

Temas relacionados: accuracy, dose delivery, insulin, prefilled pen, prefilled insulin pen

This study assess the reliability of dose selection and setting of five insulin devices by patients using auditory and sensory confirmation.

Autor: Asakura et al.

Fecha: 01/04/2010

Temas relacionados: type 2 diabetes, dose selection, auditory confirmation, sensory confirmation, audible click

Observational study in patients with type 2 diabetes failing oral agent therapy with or without basal insulin conducted to assess whether addition and self-titration of biphasic insulin aspart 70/30 (BIAsp 30) could achieve IDF and ADA glycaemic targets.

Autor: Garber AJ. et al.

Fecha: 13/04/2010

Temas relacionados: insulin initiation, OAD failures, premix insulin analogue, treatment algorithm, rapid acting insulin, biphasic insulin aspart

This 26-week study compared two insulin regimens in patients with type 2 diabetes who were uncontrolled by oral antidiabetic agents (OADs) with or without basal insulin. After discontinuation of OADs, participants were randomized to analogue basal-bolus therapy or biphasic insulin aspart.

Autor: Liebl A. et al.

Fecha: 13/04/2010

Temas relacionados: insulin analogue, type 2 diabetes, PREFER, oral antidiabetic drugs, basal-bolus, insulin detemir, insulin aspart, biphasic insulin aspart

This study compared the pharmacodynamics and pharmacokinetics of biphasic insulin aspart 30, 50 and 70 in a glucose clamp trial.

Autor: Heise T. et al.

Fecha: 13/04/2010

Temas relacionados: biphasic insulin aspart, BIAsp 30, BIAsp 50, BIAsp 70, glucose clamp trial, pharmacodynamics, pharmacokinetics

This study compared the postprandial glycaemic control achieved with meal-related insulin aspart injected immediately before a meal with that injected immediately after a meal.

Autor: Jovanovic L. et al.

Fecha: 13/04/2010

Temas relacionados: postprandial glucose concentration, meal-related insulin, insulin-to-carbohydrate ratio, carbohydrate counting

The aim of this randomized, open-label, crossover study was to compare two types of needle design and diameter in patients with diabetes injecting insulin.

Autor: Iwanaga M, Kamoi K

Fecha: 13/04/2010

Temas relacionados: patient perceptions, injection pain, anxiety, needles, injecting insulin, diabetes

This 3-year study aimed to evaluate the long-term safety and efficacy of insulin aspart in people with type 1 diabetes. It was a 30-month extension of study of 753 people with type 1 diabetes randomized to treatment with insulin aspart or unmodified human insulin before meals, in combination with NPH insulin.

Autor: Home PD

Fecha: 13/04/2010

Temas relacionados: insulin aspart, pre-meal insulin, safety, efficacy, long-term safety, long-term efficacy, type 1 diabetes, human insulin, NPH

A study comparing the injection force requirements for four insulin pen-type injection device.

Autor: Toraishi et al.

Fecha: 13/04/2010

Temas relacionados: injection devices, insulin delivery, insulin pen, injection force

Study of the associations of BMI, overweight and obesity with cardiovascular disease in type 2 diabetes patients.

Autor: Eeg-Olofsson

Fecha: 19/05/2010

Temas relacionados: BMI, diabetes, Cardiovascular diseases, mortality, epidemiology, obesity

Study comparing the IGF-1 receptor binding properties and metabolic and mitogenic potencies of insulin aspart, insulin lispro, insulin glargine, insulin detemir and insulin analogues.

Autor: Kurtzhals P. et al.

Fecha: 18/05/2010

Temas relacionados: insulin lispro, insulin glargine, insulin detemir, insulin analogues

The objective of this study was to compare the safety and efficacy of biphasic insulin aspart 70/30 (BIAsp 70/30, prebreakfast and presupper) with once-daily insulin glargine in patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs (OADs).

Autor: Raskin

Fecha: 21/05/2010

Temas relacionados: biphasic insulin, biphasic insulin analogue, premix insulin, premix insulin analogue, basal insulin, basal insulin analogue, insulin initiation, type 2 diabetes, safety, efficacy, starting insulin

This open label study compared the usability and patient preference for thin wall needles versus regular wall needles designed for use with insulin pens.

Autor: Siegmund

Fecha: 21/05/2010

Temas relacionados: thin wall, needle technology, usability, patient preference, regular wall, injection pain, anxiety, insulin pen, insulin needle, insulin pen needle

Randomized, multi-centre, double-blind, stratified, two period, crossover trial undertaken to assess the pharmacokinetics and pharmacodynamics of insulin aspart injected immediately before compared with regular human insulin injected 30 min before a Medit

Autor: Perriello et al

Fecha: 31/05/2010

Temas relacionados: rapid acting insulin analogue, mealtime glucose, prandial control, glycaemic control, type 2 diabetes, insulin aspart